							_
NULOJIX® (BELATACEPT) PRESCRIBER ORD	ER FORM						
Patient Name:		Date of Birth:					
Address:							
Phone:		Height:	:	_ $\square$ inches $\square$	cm	Weight:	_
	Clinica	al Informat	ion				
Primary Diagnosis Description:					ICD-1	10 Code:	
☐ Yes – date of first dose:					1		
Is this the first dose? $\square$ No – date of next dose due:							
	Nulojix® (bel		escript	ion			
Nulojix® (belatacept) refill as directed x 1 year							
IV Regimen: Induction Phase Dose: 10mg per kg							
☐ Maintenance Phase Dose: 5mg per	_			-	eginnin	g	·
☐ Other:							
Dose will be rounded to the nearest 12.5mg increment. Will b		•	•	ofessional.			
A popularia Vit	Anci	illary Ordei	rs				
Anaphylaxis Kit							
If this is a 1 <sup>st</sup> infusion dose, would you like Option Car $\Box$ Yes $\Box$ No	e Health to p	provide an a	ınaphyl	axis kit with the	1 <sup>st</sup> dose	e?	
⊔ res ⊔ No Dosage: □ Epinephrine 0.3 mg (> 30 kg), 0.15 mg	r (15 to 30 kg	) or 0 01 m	ng/kg (<	· 15 kg) SO or IM	у 1· ге	neat x 1 in 5 to 1	5 min PRN
□ Diphenhydramine 25 mg (> 30 kg), 0:13 mg	_						
□ 0.9% Sodium Chloride 500 mL (> 30 kg		_				(	MN no improvement
Medication Orders  Acetaminophen 650 mg PO 30 min before in may decline.  Diphenhydramine 25 mg PO 30 min before in Patient may decline.							
☐ Methylprednisolone Sodium Succinate 40 mg IV push 20 minutes prior to infusion.							
□ Other:							
IV Flush Orders							
□ Peripheral: □ Implanted Port: □ Implanted Port: □ Unstant or details □ Peripheral: □ O.9% Sodium Chloride 2 to 3 mL pre-/post-use. □ 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr. if accessed or weekly to monthly if not accessed.							
Lab Orders	,	,		,		,	,
☐ No labs ordered at this time.							
Other:	omo or altor	nata cara s	otting	Pofill above and	رم بعدالا	rdare as directos	ly 1 year
Skilled nurse to administer doses intravenously in the h  I certify that the use of the indicated treatn							
recruyy that the use of the maleuted treath	iene is medie	uny necess	ary, arre	a i wiii be sapei v	ising th	e patient streat	mene.
Prescriber Signature:						Date:	
	Prescrit	ber Informa	ation				
Prescriber Name:		Phone:		Fax:			
Address:		NPI:					
City, State:	Zip:		Office Contact:				
Fax completed form, insurance information, and clinica	l documenta	tion to:					

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.